Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug-eluting stent penetration

This article was originally published in The Gray Sheet

Executive Summary

The decline in use of drug-eluting stents in the U.S. reached a new low in the fourth quarter of 2007 - 62% of all stent placements - according to a survey of 75 hospitals by consultant Goodroe Healthcare Solutions. That figure is down from an average of 78% in Q4 of 2006 based on last year's Goodroe survey, and 75% in January (1"The Gray Sheet" Jan. 22, 2007, p. 11). The share of Johnson & Johnson/Cordis' Cypher and Boston Scientific's Taxus DES compared with bare-metal stents has held steady since September, the data shows

You may also be interested in...

Hospital Survey Illustrates Drug-Eluting Stent Use Decline In Fourth Quarter

U.S. drug-eluting stent utilization rates markedly declined in the fourth quarter of 2006, most significantly in the last month of the year, as doctors chose to use bare-metal stents more frequently due to potential safety risks, a recent survey of about 65 hospitals suggests

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts